Predictive value of apoptotic microparticles to mononuclear progenitor cells ratio in advanced chronic heart failure patients

Abstract

We demonstrated that EMP to MPC ratio is considered an important indicator of an imbalance between angiogenic and apoptotic responses with possible relation to cardiovascular outcomes in post-discharge patients with clinical stabilization after ischemic ADHF.

Number of Circulating Endothelial Progenitor Cells as a Predictive Biomarker of Heart Failure

“…Formerly, an exhaustion of circulating number of EPCs labeled as CD34+ and/or CD133+, AC133+, endothelial cell markers (CD309, CD31, CD 144) was found in patient with asymptomatic and symptomatic HF, while there are several controversies regarding the role of different immune phenotypes of EPCs in tissue reparation [6][7][8][9]. Additionally, there is a suggestion that the lowered number of EPCs in circulation may significantly relate to pre-existed cardiovascular risk factors including diabetes, obesity, impaired fasting glucose, hypothyroidism [10][11][12][13].…”

The number of red blood cell-derived microparticles in predicting periprocedural adverse effects in acute STsegment elevation myocardial infarction patients

“…Therefore, RBC-MPs are able to activate endothelium in visceral organs and thereby influence vasoconstriction and direct injury of them [56,57]. In this context, RBC-MPs measured in the peripheral blood may be sensitive markers of the thrombo-occlusive vascular process developing in the coronary arteries of STEMI-patients [58,59]. Although RBC-MPs have usually not been incorporated into predictive analysis due their small sizes and limited resolution of traditional equipment, their relations to the biomarker of cardiovascular repair and their impact on prognosis after primary PCI in STEMI subjects and probably in non-STEMI patients appears to be plenty promising.…”

Impaired Pattern of Endothelial Cell-Derived Microparticles in Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection Fraction

“…has not yet obviously defined [24][25][26], whereas in HFrEF the increased number of circulating apoptotic EMPs has associated with merged 3-year HF-related death rate, all-cause mortality rate, and a risk of recurrent admission to the hospital [27,28]. In contrast, apoptosisrelated Annexin V-binding EMPs have elevated at early stage of HFpEF associated with co-morbidities, such as insulin resistance, obesity, diabetes, and merited to clinical outcomes [29][30].…”